Skip To Main Content
IFRS Adjusted on Muck Rack

IFRS Adjusted

As seen in: Sparda-Bank web.Börsenforum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to IFRS Adjusted’s profile

Articles by IFRS Adjusted

PSD Bank Rhein-Ruhr eG

|
By IFRS Adjusted, Susanne Schaffert, Interest paid
| Sparda-Bank web.Börsenforum
* Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest * Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types * Multiple milestones achieved in 2026, including initiation of six pivotal trials - five for pumitamig and one for B7-H3-targeting ADC candidate elfetabart drozuntecan; upcoming 2026 catalysts include three...
Open in Who Shared View Duplicates (148) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By mRNA cancer, IFRS Adjusted, BioNtech will
| Sparda-Bank web.Börsenforum
* Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb * Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs * Catalyst-rich year ahead with six late-stage pipeline data readouts expected across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies * COVID-19 2026/2027 season variant-adapted...
Open in Who Shared View Duplicates (153) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By mRNA cancer, Net profit, IFRS Adjusted
| Sparda-Bank web.Börsenforum
* BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies * Increased focus on PD-L1(1)/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb * Full year 2025 revenues of EUR2.9 billion(2), net loss of EUR1.1 billion (adjusted(3 )net loss of EUR0.1 billion) and diluted loss...
Open in Who Shared View Duplicates (123) Issue with article?
Show More